Article
Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening.
PLoS neglected tropical diseases - 1 Dec 2017
Ortiz Diana, Guiguemde W Armand, Hammill Jared T, Carrillo Angela K, Chen Yizhe, Connelly Michele, Stalheim Kayla, Elya Carolyn, Johnson Alex, Min Jaeki, Shelat Anang, Smithson David C, Yang Lei, Zhu Fangyi, Guy R Kiplin, Landfear Scott M
Abstract excerpt
Leishmaniasis is a parasitic infection that afflicts approximately 12 million people worldwide. There are several limitations to the approved drug therapies for leishmaniasis, including moderate to severe toxicity, growing drug resistance, and the need for extended dosing. Moreover, miltefosine is currently the only orally available drug therapy for this infection. We addressed the pressing need for new therapies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.